Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Ekologia - Ecology Endocrine Regulations General Physiology and Biophysics Neoplasma 2026 Ahead of print 2025 2024 2023 2022 2021 2020 2019 2018 2016 2017 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudba 2025Webshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Neoplasma Vol.73, 2026, No.1, p. 52–58 |
||
| Title: Efficacy and safety of adebrelimab plus bevacizumab in combination with hepatic artery infusion chemotherapy for advanced stage hepatocellular carcinoma: a retrospective cohort study | ||
| Author: Chen Li, Letao Lin, Shuanggang Chen, Gulijiayina Nuerhashi, Hongtong Tan, Chunyong Wen, Yujia Wang, Guanglei Zheng, Ruizhi Tang, Jiayu Pan, Lujun Shen, Weijun Fan | ||
| Abstract: Hepatic arterial infusion chemotherapy using a combination of oxaliplatin, fluorouracil, and leucovorin (HAIC-FOLFOX) has shown promise for patients with advanced-stage hepatocellular carcinoma (HCC). In this study, we aim to evaluate the efficacy and safety of combining adebrelimab (anti-PD-L1 antibody) and bevacizumab with HAIC-FOLFOX for HCC patients in BCLC stage C. This retrospective study included 32 untreated advanced-stage HCC patients receiving HAIC-FOLFOX combined with adebrelimab and bevacizumab as first-line therapy. The primary endpoint is overall response rate (ORR) based on the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. From January 14th, 2024, to December 5th, 2024, a total of 32 patients received the triplet combination of HAIC-FOLFOX, adebrelimab, and bevacizumab. Median follow-up time was 6.1 months. According to RECIST v1.1 criteria, the confirmed ORR was 71.8% (95% CI: 55.4-88.3 %), with a disease control rate (DCR) of 93.7% (95% CI: 84.9-99.9%). Only one case (3.1%) had a grade 3 treatment-related adverse event (rash), which could be alleviated after symptomatic management. The combination of adebrelimab, bevacizumab, and HAIC-FOLFOX demonstrated encouraging results and manageable safety concerns for patients with HCC at BCLC stage C. |
||
| Keywords: hepatic arterial infusion chemotherapy; adebrelimab; bevacizumab; hepatocellular carcinoma | ||
| Year: 2026, Volume: 73, Issue: 1 | Page From: 52, Page To: 58 | |
| doi:10.4149/neo_2025_200508N198 |
||
|
|
 download file |
|